RxDoctor Payments Data

Salman Akhtar, MD

Cardiovascular Disease · Las Vegas, NVNPI 1639168966

Payments from drug & device makers

$2,360in general payments, 2019–2025

Across 70 payments — averaging $33.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$539
  • Abbott$320
  • Novartis$224
  • Boston Scientific$218
  • Abiomed$160
  • Kiniksa Pharmaceuticals International, PLC$146
  • plus $753 from 14 others

What the payments were for

  • Travel & lodging$2149%
  • Food & beverage$2,14691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,360 in reported general payments places this provider in the 40th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$217,763
Medicare patients
1,800
Services billed
3,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$99,365
EntrestoSacubitril/Valsartan43$71,672
XareltoRivaroxaban16$22,822
JardianceEmpagliflozin13$16,837
FarxigaDapagliflozin Propanediol11$11,892
Repatha SureclickEvolocumab13$7,119
Metoprolol Succinate206$2,662
Ranolazine ErRanolazine13$2,204
Rosuvastatin Calcium146$1,912
Flecainide Acetate36$1,521
Nifedipine ErNifedipine43$1,303
Ezetimibe52$853
Nebivolol Hcl19$810
Atorvastatin Calcium73$661
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$99,36586 claims
NovartisEntresto$224$71,67243 claims
Johnson & JohnsonXarelto$12$22,82216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →